DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
APD791 is an investigational drug.
There have been 5 clinical trials for APD791. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2021.
The most common disease conditions in clinical trials are Acute Coronary Syndrome, Raynaud Disease, and Neoplasm Metastasis. The leading clinical trial sponsors are Arena Pharmaceuticals, Asan Medical Center, and IlDong Pharmaceutical Co Ltd.
There are thirteen US patents protecting this investigational drug and one hundred and twenty-six international patents.
Recent Clinical Trials for APD791
|A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis||Arena Pharmaceuticals||Phase 2|
|Dose-escalation, Repeated and Single Oral Dosing Study||Asan Medical Center||Phase 1|
|Dose-escalation, Repeated and Single Oral Dosing Study||IlDong Pharmaceutical Co Ltd||Phase 1|
Top disease conditions for APD791
Top clinical trial sponsors for APD791
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|APD791||⤷ Try it Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||⤷ Try it Free|
|APD791||⤷ Try it Free||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||⤷ Try it Free|
|APD791||⤷ Try it Free||Compartmented pharmaceutical dosage forms||Triastek, Inc. (Nanjing, CN)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|APD791||Australia||AU2017261372||2036-05-05||⤷ Try it Free|
|APD791||Canada||CA3023278||2036-05-05||⤷ Try it Free|
|APD791||China||CN107847398||2036-05-05||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|